Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hemodynamic Response to Exercise in HFpEF Patients After Upregulation of SERCA2a
NCT02772068Phase 1Completed
- Start
- Sep 2015
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of istaroxime in heart failure with preserved ejection fraction (HFpEF) (2 arms). Primary endpoint: Change in cardiac filling pressures (pulmonary capillary wedge pressure) at 90 minutes. Started Sep 2015; status: completed.
02
Drugs
istaroxime
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT02772068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02772068.